1. Introduction {#sec1}
===============

Intracranial aneurysm (IA) is a balloon-like dilation of the cerebral artery or vein, with an incidence rate of 2-3% in the general population \[[@B1]\]. Rupture of IA can cause 85% of subarachnoid hemorrhage, a death of approximately 50% of the cases, and a severe disability in 30% of the cases \[[@B2]--[@B4]\]. It is well accepted that lifestyle diseases including hypertension, cigarette smoking, excessive alcohol intake, and obesity are major risk factors for the development of IA \[[@B5]--[@B7]\]. Besides these factors, genetic factors are known to contribute to the physiopathology of IA \[[@B8], [@B9]\]. Approximately 20% of IA patients have a family history, and a 7-fold higher risk of IA was observed among first-degree relatives compared to second-degree relatives \[[@B8], [@B10]--[@B12]\]. Our previous work also identified some susceptibility loci for the development of IA, such as rs13293512 in the promoter of let-7 and rs4705342 in the promoter of miR-143/145 cluster \[[@B13], [@B14]\].

Previously, a genome-wide association study (GWAS) identified that 11p15.5 was a risk loci of IA, and a strong association of Bet1 Golgi vesicular membrane trafficking protein like (*BET1L*) rs2280543 at chromosome 11p15.5 with IA susceptibility was observed in a Japanese population \[[@B15]\]. However, little is known to date how the polymorphism influences IA development. Long noncoding RNAs (lncRNAs), single-stranded noncoding RNAs of more than 200 nucleotides in length, were recently found to be implicated in many human diseases, including IA by regulating gene expression at the transcription level or posttranscription level \[[@B16]--[@B18]\]. Amounts of lncRNAs were reported to be aberrantly expressed in IA, including *H19* \[[@B19], [@B20]\]. The lncRNA *H19*, imprinted maternally expressed transcript, is located at chromosome 11p15.5 that is the susceptibility loci of IA \[[@B15], [@B21]\]. Increasing evidence has shown that *H19* is involved in the process of hypertension and atherosclerosis pathology \[[@B22]--[@B26]\], which are important risk factors for the development of IA \[[@B5]--[@B7]\].

Genetic variants in *H19* have been demonstrated to play a key role in ischemic stroke \[[@B27]\] and coronary artery disease \[[@B28]\]. TT genotype of rs217727 in *H19* was significantly associated with an increased risk of ischemic stroke, and the association remained after adjusting for confounding risk factors of stroke \[[@B27]\]. The increased risk of the rs217727 TT genotype in *H19* was also observed in coronary artery disease \[[@B28]\]. However, no study to date has investigated the association between single-nucleotide polymorphisms (SNPs) in *H19* and the risk of IA. In this work, a replication study of GWAS-discovered IA risk loci rs2280543 in *BET1L* was performed in a Chinese Han population. Moreover, the effect of potentially functional SNPs in *H19* and their interaction with *BET1L* rs2280543 were also examined.

2. Materials and Methods {#sec2}
========================

2.1. Ethics Statement {#sec2.1}
---------------------

The case-control study was approved by the Institutional Review Board of the West China Hospital of Sichuan University, and written informed consent was provided by each participant. In cases with unconscious or illiterate patients, the written consent was completed by their relatives.

2.2. Study Population {#sec2.2}
---------------------

The study subjects were enrolled from the West China Hospital of Sichuan University between January 2008 and July 2016, which included 542 IA patients and 588 controls. Detailed information of the study subjects was described previously \[[@B13], [@B14]\]. For the cases, peripheral blood samples were taken from patients who were definitely diagnosed with IA by digital subtraction angiography. Clinical information was also collected, including age, gender, systolic pressure, diastolic pressure, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, the number of aneurysm, ruptured or unruptured aneurysm, and familial aneurysm or not. Patients who had hypertension, head trauma, intracranial atherosclerosis, and/or other nervous system diseases were excluded from the case group. Controls who came to the same hospital for a routine examination of physical condition at the same time period were selected. Controls with previous hypertension and/or some common nervous system diseases, such as stroke, traumatic brain injury, Alzheimer\'s disease, and Parkinson\'s disease, were excluded. All subjects were genetically unrelated Han Chinese living in Sichuan province or the surrounding area of southwest China.

2.3. SNP Selection {#sec2.3}
------------------

GWAS-identified risk loci *BET1L* rs2280543 was selected. Moreover, potentially functional SNPs in lncRNA *H19* were selected if they met the following criteria: (a) minor allele frequency \> 0.1 in the Chinese Han Beijing population of the 1000 Genomes Project and (b) in silico prediction of functional SNPs. Finally, 3 out of 12 SNPs in *H19* were examined in this study since they have potential function, that is, the *H19* rs217727 C allele influencing circulating concentrations of insulin-like growth factor 2 (IGF2) \[[@B29]\]; the rs2839698 CT and TT genotypes resulting in higher levels of H19 \[[@B30]\]; and the rs2735971 A/G having different binding affinity to transcriptional factor CCAAT/enhancer-binding protein alpha (C/EBP*α*).

2.4. Genotyping {#sec2.4}
---------------

Genomic DNA was extracted from peripheral blood leukocytes using the Bioteke DNA isolation kit according to the manufacturer\'s instructions (Bioteke, Beijing, China). Genotyping analysis for the 4 SNPs was performed using the TaqMan allelic discrimination assay on an ABI 7900HT real-time PCR system (Applied Biosystems, CA, USA) \[[@B31], [@B32]\]. For quality control, the results were read by 2 research staff members blindly. Moreover, about 5% of the samples were selected for Sanger sequencing, and the concordance rates between duplicate samples were 100%.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The SPSS software (version 19.0, SPSS Inc., Chicago, IL) was used for statistical analysis. Hardy-Weinberg equilibrium (HWE) was tested to compare the observed genotype distributions with the expected among controls using the *χ*^2^ test with one degree of freedom. The genotype frequencies of the 4 SNPs between IA cases and controls were compared using the *χ*^2^ test. Associations between the 4 SNPs and IA risk were evaluated by calculating odds ratios (ORs) and their 95% confidence intervals (CIs). ORs were adjusted by age, gender, and familial history of IA using the logistic regression analysis. In multiple comparisons, Bonferroni corrections were used to correct the alpha level of 0.0125 (0.05/4). Multifactor dimensionality reduction (MDR) analysis was carried out to assess *BET1L*-*H19* interaction. All statistical tests were two-sided, and a *P* value \< 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of the Study Population {#sec3.1}
--------------------------------------------

The characteristics of the study population are summarized in [Table 1](#tab1){ref-type="table"}. The mean age of the cases was 51.8 ± 11.8 years, and 39.3% of the patients were male. The mean age of the controls was 51.1 ± 9.1 years, and 36.9% of the controls were male. There was no significant difference between cases and controls according to age (*P* = 0.26) and gender (*P* = 0.41), indicating that the controls were frequency-matched to cases based on age and gender. Among the patients, 86.3% were diagnosed with single intracranial aneurysm, 88.0% with ruptured aneurysm, and 90.0% with nonfamilial aneurysm.

3.2. Association of the *BET1L* and *H19* Polymorphisms with IA Risk {#sec3.2}
--------------------------------------------------------------------

The association between the *BET1L* and *H19* polymorphisms and IA risk was presented in [Table 2](#tab2){ref-type="table"}. The genotype frequencies of the 4 SNPs in controls were in HWE (*P* \> 0.05). For the *BET1L* rs2280543, an increased risk was significantly associated with the CT genotype (adjusted OR = 1.43, 95% CI: 1.08-1.90, *P* = 0.01) and the CT/TT genotypes (adjusted OR = 1.48, 95% CI: 1.12-1.94, *P* = 0.005) compared with the CC genotype. The similarly increased risk was also observed in the additive model (adjusted OR = 1.40, 95% CI: 1.11-1.78, *P* = 0.005) and allele comparison (adjusted OR = 1.44, 95% CI: 1.13-1.83, *P* = 0.003). For the *H19* rs217727, an increased risk was significantly associated with the TT genotype (adjusted OR = 1.90, 95% CI: 1.35-2.67, *P* \< 0.001), T allele (adjusted OR = 1.38, 95% CI: 1.16-1.64, *P* \< 0.001), and additive model (adjusted OR = 1.33, 95% CI: 1.13-1.56, *P* \< 0.001). For the *H19* rs2839698 and rs2735971, no significant difference of the genotype distributions was found between cases and controls. After stratification analyses according to the number of aneurysms and ruptured-versus-unruptured IA, we failed to find any association between the 4 SNPs and the clinical information (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}).

3.3. Combined Analyses {#sec3.3}
----------------------

Combined analyses revealed that individuals with the rs2280543 CC-rs217727 CT/TT genotypes had a 2.35-fold increased risk of IA compared to those with the rs2280543 CC-rs217727 CC genotypes (95% CI: 1.77-3.12, *P* \< 0.001); individuals with the rs2280543 CT/TT-rs2735971 GG genotypes had a 1.63-fold increased risk of IA compared to those with the rs2280543 CC-rs2735971 GG genotypes (95% CI: 1.18-2.25, *P* = 0.003); and individuals with the rs217727 CT/TT-rs2735971 GG genotypes had a 1.46-fold increased risk of IA compared to those with the rs217727 CC-rs2735971 GG genotypes (95% CI: 1.09-1.95, *P* = 0.01) ([Table 5](#tab5){ref-type="table"}).

3.4. Interaction Analysis {#sec3.4}
-------------------------

*BET1L*-*H19* interaction analysis showed that the best candidate model was rs2280543-rs217727-rs2839698, with an accuracy of 0.65 and cross-validation consistency of 10/10 (OR = 3.36, 95% CI: 2.60-4.34, *P* \< 0.001) ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

In the present study, we examined whether *BET1L* and *H19* polymorphisms were associated with the risk of IA. We found a statistically significant higher risk of *BET1L* rs2280543 CT, CT/TT genotypes, and T allele among IA patients. The increased risk of IA was also observed in individuals carrying the *H19* rs217727 TT genotype and T allele. Combined analyses revealed that the rs2280543 CC-rs217727 CT/TT, rs2280543 CT/TT-rs2735971 GG, and rs217727 CT/TT-rs2735971 GG genotypes were related to the risk of IA. Interaction analysis showed that the 3-loci model of rs2280543-rs217727-rs2839698 contributed to an increased risk of IA. Using the Quanto software, we computed the statistical power. Our study has more than 81% power if the OR was set at 1.7 under a dominant model. These findings suggest that the GWAS-discovered risk loci *BET1L* rs2280543 may increase IA susceptibility by interacting with lncRNA *H19*.

In 2012, Low et al. conducted a GWAS including 1383 IA patients and 5484 control individuals and identified a susceptibility loci *BET1L* rs2280543 at chromosome 11p15.5 in a Japanese population \[[@B15]\]. Further replication analysis using an additional set of 1048 IA cases and 7212 controls validated this result \[[@B15]\]. In this study, we selected 542 IA patients and 588 age- and gender-matched controls and found that the *BET1L* rs2280543 T variant increased the risk of IA in a Chinese population, which confirmed previous finding \[[@B15]\]. BET1L, encoded by *BET1L* gene, can facilitate the Golgi vesicular membrane trafficking process \[[@B33]\]. However, little is known to date of the biological function of BET1L in IA even though there is a previous report of rs2280543 influencing *BET1L* expression levels in multiple human tissues \[[@B34]\].

The lncRNA *H19*, located on GWAS-discovered IA susceptibility loci of chromosome 11p15.5, was reported to be differentially expressed in IA \[[@B19], [@B20]\]. Silencing of *H19* can inhibit proliferation and induce apoptosis of vascular smooth muscle cells by regulating the miR-148b/WNT/*β*-catenin pathway \[[@B26]\], whereas overexpression of *H19* can promote proliferation and suppress apoptosis by regulating MAPK and NF-*κ*B signaling pathway \[[@B23]\], implicating the important values of *H19* in atherosclerosis and hypertension that are risk factors for the formation of IA \[[@B5]--[@B7]\]. With regard to the *H19* polymorphisms in vascular diseases, Gao et al. reported that the *H19* rs217727 T variant was associated with an increased risk of coronary artery disease in an additive model, dominant model, and recessive model, while the rs2067051 A variant was associated with a decreased risk of coronary artery disease in an additive model and recessive model \[[@B28]\]. Zhu et al. reported that the *H19* rs217727 TT genotype was associated with an increased risk of ischemic stroke, especially in small vessel ischemic stroke \[[@B27]\]. Based on this background, we hypothesized that the *BET1L* rs2280543 may be involved in the occurrence of IA by interacting with lncRNA *H19* polymorphisms. Our findings confirmed this hypothesis. We found that not only the *H19* rs217727 TT genotype but also the combined genotypes of rs2280543 CC-rs217727 CT/TT and rs2280543 CT/TT-rs2735971 GG were associated with an increased risk of IA. Of note, we found that *BET1L*-*H19* interaction (rs2280543-rs217727-rs2839698) conferred the risk of IA. These findings indicate that the *BET1L* rs2280543 increased IA risk partly by interacting with the lncRNA H19 polymorphisms.

We have to admit some limitations in this work. All individuals included in this study were Han Chinese, and thus, these findings cannot be directly extended to other ethnicities until confirmation results were obtained. Gene-gene and gene-environment interactions were important for an association study. *BET1L-H19* interaction was performed in this study. However, gene-environment interaction cannot be assessed due to insufficient data. Control subjects were hospital-based and did not undergo magnetic resonance angiography screening. The possibility of selection bias therefore cannot be ruled out. Additionally, clinical information is incomplete, such as unavailable data of body mass index. Despite these limitations, replication analysis in this study verified the risk factor of *BET1L* rs2280543 in IA occurrence. Moreover, the lncRNA *H19* may singly and interactively with *BET1L* contribute to the susceptibility of IA.

In conclusion, we provided the first evidence that GWAS-discovered IA susceptibility loci *BET1L* rs2280543 may contribute to the risk of IA by interacting with lncRNA *H19* in the Chinese population. Further evaluation of the exact mechanism of *BET1L* and *H19* in the etiology of IA will be of great value, which will be beneficial for us to achieve a comprehensive understanding of GWAS-identified SNPs relevant to the development of IA.
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###### 

Demographics of controls and patients with IA.

  ------------------------------------------------------------------------------------
                                         Controls\     Patients with IA\   *P* value
                                         *n* = 588     *n* = 542           
  -------------------------------------- ------------- ------------------- -----------
  Age (year, mean ± SD)                  51.1 ± 9.1    51.8 ± 11.8         0.26

  Gender                                                                   

   Male                                  217 (36.9)    213 (39.3)          0.41

   Female                                371 (63.1)    329 (60.7)          

  Systolic pressure (mmHg, mean ± SD)    109.1 ± 9.8   107.0 ± 12.9        0.25

  Diastolic pressure (mmHg, mean ± SD)   76.5 ± 6.9    76.4 ± 6.2          0.90

  TC (mmol/L, mean ± SD)                 4.4 ± 0.5     3.9 ± 0.4           \<0.001

  TG (mmol/L, mean ± SD)                 1.2 ± 0.5     1.2 ± 0.3           0.07

  HDL-C (mmol/L, mean ± SD)              1.7 ± 0.8     1.4 ± 0.3           \<0.001

  LDL-C (mmol/L, mean ± SD)              2.1 ± 0.8     2.5 ± 0.7           \<0.001

  Multiple aneurysm                                                        

   Yes                                                 74 (13.7)           

   No                                                  468 (86.3)          

  Rupture of aneurysm                                                      

   Yes                                                 477 (88.0)          

   No                                                  65 (12.0)           

  Familial aneurysm                                                        

   Yes                                                 54 (10.0)           

   No                                                  488 (90.0)          
  ------------------------------------------------------------------------------------

IA: intracranial aneurysm; SD: standard deviation; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

###### 

Association between the *BET1L* and *H19* polymorphisms and IA risk.

  Polymorphisms       Controls, *n* = 588 (%)   Patients, *n* = 542 (%)   Adjusted OR (95% CI)^†^   *P* value
  ------------------- ------------------------- ------------------------- ------------------------- -----------
  *BET1L* rs2280543                                                                                 
   CC                 455 (77.4)                380 (70.1)                1.00                      
   CT                 123 (20.9)                147 (27.1)                1.43 (1.08-1.90)          0.01
   CT/TT              133 (22.6)                162 (29.9)                1.48 (1.12-1.94)          0.005
   Additive model                                                         1.40 (1.11-1.78)          0.005
   C allele           1033 (87.8)               907 (83.7)                1.00                      
   T allele           143 (12.2)                177 (16.3)                1.44 (1.13-1.83)          0.003
  *H19* rs217727                                                                                    
   CC                 238 (40.5)                182 (33.6)                1.00                      
   CT                 259 (44.0)                230 (42.4)                1.14 (0.87-1.49)          0.36
   TT                 91 (15.5)                 130 (24.0)                1.90 (1.35-2.67)          \<0.001
   CT/TT              350 (59.5)                360 (66.4)                1.33 (1.03-1.71)          0.03
   Additive model                                                         1.33 (1.13-1.56)          \<0.001
   C allele           735 (62.5)                594 (54.8)                1.00                      
   T allele           441 (37.5)                490 (45.2)                1.38 (1.16-1.64)          \<0.001
  *H19* rs2839698                                                                                   
   CC                 318 (54.1)                312 (57.6)                1.00                      
   CT                 221 (37.6)                194 (35.8)                0.90 (0.70-1.17)          0.44
   TT                 49 (8.3)                  36 (6.6)                  0.80 (0.50-1.27)          0.33
   CT/TT              270 (45.9)                230 (42.4)                0.88 (0.69-1.13)          0.32
   Additive model                                                         0.88 (0.73-1.06)          0.18
   C allele           857 (72.9)                818 (75.5)                1.00                      
   T allele           319 (27.1)                266 (24.5)                0.89 (0.74-1.08)          0.25
  *H19* rs2735971                                                                                   
   GG                 413 (70.2)                382 (70.5)                1.00                      
   AG                 153 (26.0)                130 (24.0)                0.86 (0.65-1.14)          0.30
   AA                 22 (3.7)                  30 (5.5)                  1.54 (0.87-2.74)          0.14
   AG/AA              175 (29.8)                160 (29.5)                0.95 (0.73-1.24)          0.70
   Additive model                                                         1.04 (0.85-1.28)          0.68
   G allele           979 (83.2)                894 (82.5)                1.00                      
   A allele           197 (16.8)                190 (17.5)                1.04 (0.83-1.30)          0.74

IA: intracranial aneurysm; OR: odds ratio; CI: confidence interval. ^†^Adjusted by age, gender, and familial history of IA.

###### 

Stratification analyses by the number of aneurysms.

  Polymorphisms       Multiple aneurysm, *n* = 74 (%)   Single aneurysm, *n* = 468 (%)   Adjusted OR (95% CI)^†^   *P* value
  ------------------- --------------------------------- -------------------------------- ------------------------- -----------
  *BET1L* rs2280543                                                                                                
   CC                 59 (79.7)                         321 (68.6)                       1.00                      
   CT/TT              15 (20.3)                         147 (31.4)                       0.56 (0.31-1.02)          0.05
   C allele           130 (87.8)                        777 (83.0)                       1.00                      
   T allele           18 (12.2)                         159 (17.0)                       0.68 (0.40-1.14)          0.13
  *H19* rs217727                                                                                                   
   CC                 20 (27.0)                         162 (34.6)                       1.00                      
   CT/TT              54 (73.0)                         306 (65.4)                       1.37 (0.79-2.38)          0.25
   C allele           72 (48.6)                         522 (55.8)                       1.00                      
   T allele           76 (51.4)                         414 (44.2)                       1.28 (0.91-1.82)          0.16
  *H19* rs2839698                                                                                                  
   CC                 46 (62.2)                         266 (56.8)                       1.00                      
   CT/TT              28 (37.8)                         202 (43.2)                       0.79 (0.48-1.31)          0.36
   C allele           115 (77.7)                        703 (75.1)                       1.00                      
   T allele           33 (22.3)                         233 (24.9)                       0.85 (0.56-1.29)          0.45
  *H19* rs2735971                                                                                                  
   GG                 53 (71.6)                         329 (70.3)                       1.00                      
   AG/AA              21 (28.4)                         139 (29.7)                       0.95 (0.55-1.64)          0.85
   G allele           123 (83.1)                        771 (82.4)                       1.00                      
   A allele           25 (16.9)                         165 (17.6)                       0.94 (0.59-1.49)          0.79

IA: intracranial aneurysm; OR: odds ratio; CI: confidence interval. ^†^Adjusted by age, gender, and familial history of IA.

###### 

Stratification analyses by ruptured aneurysm (yes vs. no).

  Polymorphisms       Ruptured aneurysm   Adjusted OR (95% CI)^†^   *P* value          
  ------------------- ------------------- ------------------------- ------------------ ------
  *BET1L* rs2280543                                                                    
   CC                 333 (69.8)          47 (72.3)                 1.00               
   CT/TT              144 (30.2)          18 (27.7)                 0.88 (0.49-1.56)   0.65
   C allele           797 (83.5)          110 (84.6)                1.00               
   T allele           157 (16.5)          20 (15.4)                 0.91 (0.55-1.52)   0.72
  *H19* rs217727                                                                       
   CC                 160 (33.5)          22 (33.8)                 1.00               
   CT/TT              317 (66.5)          43 (66.2)                 1.05 (0.60-1.82)   0.87
   C allele           522 (54.7)          72 (55.4)                 1.00               
   T allele           432 (45.3)          58 (44.6)                 1.01 (0.70-1.47)   0.94
  *H19* rs2839698                                                                      
   CC                 270 (56.6)          42 (64.6)                 1.00               
   CT/TT              207 (43.4)          23 (35.4)                 0.71 (0.41-1.21)   0.20
   C allele           714 (74.8)          104 (80.0)                1.00               
   T allele           240 (25.2)          26 (20.0)                 0.74 (0.47-1.16)   0.18
  *H19* rs2735971                                                                      
   GG                 335 (70.2)          47 (72.3)                 1.00               
   AG/AA              142 (29.8)          18 (27.7)                 0.92 (0.51-1.64)   0.77
   G allele           787 (82.5)          107 (82.3)                1.00               
   A allele           167 (17.5)          23 (17.7)                 1.04 (0.64-1.68)   0.88

IA: intracranial aneurysm; OR: odds ratio; CI: confidence interval. ^†^Adjusted by age, gender, and familial history of IA.

###### 

Combined analyses of the *BET1L* and *H19* polymorphisms with IA risk.

  Combined genotypes                  Controls (%)   IA (%)       OR (95% CI)        *P* value
  ----------------------------------- -------------- ------------ ------------------ -----------
  *BET1L* rs2280543-*H19* rs217727                                                   
  rs2280543 CC-rs217727 CC            238 (40.5)     121 (22.3)   1.00               
  rs2280543 CC-rs217727 CT/TT         217 (36.9)     259 (47.8)   2.35 (1.77-3.12)   \<0.001
  rs2280543 CT/TT-rs217727 CC         ---            61 (11.3)    ---                ---
  rs2280543 CT/TT-rs217727 CT/TT      133 (22.6)     101 (18.6)   1.49 (1.06-2.10)   0.02
  *BET1L* rs2280543-*H19* rs2839698                                                  
  rs2280543 CC-rs2839698 CC           237 (40.3)     219 (40.4)   1.00               
  rs2280543 CC-rs2839698 CT/TT        218 (37.1)     161 (29.7)   0.80 (0.61-1.05)   0.11
  rs2280543 CT/TT-rs2839698 CC        81 (13.8)      93 (17.2)    1.24 (0.88-1.76)   0.22
  rs2280543 CT/TT-rs2839698 CT/TT     52 (8.8)       69 (12.7)    1.44 (0.96-2.15)   0.08
  *BET1L* rs2280543-*H19* rs2735971                                                  
  rs2280543 CC-rs2735971 GG           325 (55.3)     265 (48.9)   1.00               
  rs2280543 CC-rs2735971 AG/AA        130 (22.1)     115 (21.2)   1.09 (0.81-1.46)   0.59
  rs2280543 CT/TT-rs2735971 GG        88 (15.0)      117 (21.6)   1.63 (1.18-2.25)   0.003
  rs2280543 CT/TT-rs2735971 AG/AA     45 (7.7)       45 (8.3)     1.23 (0.79-1.91)   0.37
  *H19* rs217727-*H19* rs2839698                                                     
  rs217727 CC-rs2839698 CC            128 (21.8)     105 (19.4)   1.00               
  rs217727 CC-rs2839698 CT/TT         110 (18.7)     77 (14.2)    0.85 (0.58-1.26)   0.42
  rs217727 CT/TT-rs2839698 CC         190 (32.3)     207 (38.2)   1.33 (0.96-1.84)   0.09
  rs217727 CT/TT-rs2839698 CT/TT      160 (27.2)     153 (28.2)   1.17 (0.83-1.64)   0.38
  *H19* rs217727-*H19* rs2735971                                                     
  rs217727 CC-rs2735971 GG            175 (29.8)     128 (23.6)   1.00               
  rs217727 CC-rs2735971 AG/AA         63 (10.7)      54 (10.0)    1.17 (0.76-1.80)   0.47
  rs217727 CT/TT-rs2735971 GG         238 (40.5)     254 (46.9)   1.46 (1.09-1.95)   0.01
  rs217727 CT/TT-rs2735971 AG/GG      112 (19.0)     106 (19.6)   1.29 (0.91-1.84)   0.15

IA: intracranial aneurysm; OR: odds ratio; CI: confidence interval.

###### 

Interaction analysis of the *BET1L* and *H19* polymorphisms and risk of IA.

  Best candidate models          Accuracy   Cross-validation consistency   OR (95% CI)        *P* value
  ------------------------------ ---------- ------------------------------ ------------------ -----------
  rs217727                       0.55       10/10                          1.70 (1.24-2.32)   0.001
  rs2280543-rs217727             0.64       10/10                          3.10 (2.40-4.01)   \<0.001
  rs2280543-rs217727-rs2839698   0.65       10/10                          3.36 (2.60-4.34)   \<0.001

IA: intracranial aneurysm; OR: odds ratio; CI: confidence interval.
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